Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
2.050
+0.060 (3.02%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Camp4 Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Camp4 Therapeutics stock have an average target of 19.33, with a low estimate of 17 and a high estimate of 23. The average target predicts an increase of 842.93% from the current stock price of 2.05.
Analyst Consensus: Buy
* Price targets were last updated on Nov 5, 2024.
Analyst Ratings
The average analyst rating for Camp4 Therapeutics stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Nov 5, 2024 |
| Leerink Partners | Leerink Partners | Buy Initiates $17 | Buy | Initiates | $17 | +729.27% | Nov 5, 2024 |
| JP Morgan | JP Morgan | Buy Initiates $23 | Buy | Initiates | $23 | +1,021.95% | Nov 5, 2024 |
| Piper Sandler | Piper Sandler | Buy Initiates $18 | Buy | Initiates | $18 | +778.05% | Nov 5, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $8.05 → $6.9 | Strong Sell | Maintains | $8.05 → $6.9 | +236.59% | Jan 11, 2024 |
Financial Forecast
Revenue This Year
229.50K
from 652.00K
Decreased by -64.80%
Revenue Next Year
102.00K
from 229.50K
Decreased by -55.56%
EPS This Year
-3.03
from -11.04
EPS Next Year
-2.71
from -3.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 525,000 | 420,000 | n/a |
| Avg | 229,500 | 102,000 | n/a |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -19.5% | 83.0% | - |
| Avg | -64.8% | -55.6% | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.93 | -2.24 | -2.68 |
| Avg | -3.03 | -2.71 | -2.86 |
| Low | -3.23 | -2.98 | -2.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.